Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 2/20 | 0.48 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.48 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10472380 | 0.95 | HSD17B1 (0.50) | HSD17B1HSD17B2CYP2E1CYP3A4CYP2A6 | |
| SCHEMBL16706001 | 0.95 | HSD17B1 (0.50) | HSD17B1HSD17B2CYP2E1CYP3A4CYP2A6 | |
| SCHEMBL13885536 | 0.95 | RAB9A (0.52) | HSD17B1HSD17B2CYP2E1CYP3A4CYP2A6 | |
| Boric Acid SCHEMBL31280988 | 0.91 | HSD17B1 (0.47) | HSD17B1HSD17B2CYP2E1CYP3A4CYP2A6 | |
| SCHEMBL23555791 | 0.89 | HSD17B1 (0.50) | HSD17B1HSD17B2CYP2E1CYP3A4CYP2A6 | |
| SCHEMBL9927249 | 0.87 | APP (0.48) | HSD17B1HSD17B2RAB9ANPC1ALDH1A1 | |
| SCHEMBL13125887 | 0.84 | APP (0.50) | HSD17B1HSD17B2CYP2E1CYP3A4CYP2A6 | |
| SCHEMBL13125897 | 0.84 | APP (0.50) | HSD17B1HSD17B2CYP2E1CYP3A4CYP2A6 | |
| SCHEMBL13125875 | 0.84 | APP (0.50) | HSD17B1HSD17B2CYP2E1CYP3A4CYP2A6 | |
| SCHEMBL10300218 | 0.84 | APP (0.46) | HSD17B1HSD17B2RAB9ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 531 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119101029-A | Photochromic diaryl ethylene compound and preparation method and application thereof | 济宁医学院 | 2024-12-10 | — | — | CN | claimed |
| WO-1995020637-A2 | HYDROCARBON OIL-AQUEOUS FUEL AND ADDITIVE COMPOSITIONS | MEG S.N.C. DI SCOPELLITI SOFIA & C. (IT) | 1995-08-03 | — | — | WO | claimed |
| CN-119101029-B | Photochromic diaryl ethylene compound and preparation method and application thereof | 济宁医学院 | 2025-06-13 | — | — | CN | disclosed |
| CN-119751410-A | Method for thoroughly reducing aromatic oxide | 郑州大学 | 2025-04-04 | — | — | CN | disclosed |
| CN-119101029-A | Photochromic diaryl ethylene compound and preparation method and application thereof | 济宁医学院 | 2024-12-10 | — | — | CN | disclosed |
| EP-4395521-A1 | CONDENSED CYCLIC COMPOUND, LIGHT-EMITTING DEVICE COMPRISING THE CONDENSED CYCLIC COMPOUND, AND ELECTRONIC APPARATUS COMPRISING THE LIGHT-EMITTING DEVICE | Samsung Display Co., Ltd. (KR) | 2024-07-03 | — | — | EP | disclosed |
| EP-4389738-A1 | SOS1 INHIBITOR AND USE THEREOF | Kanaph Therapeutics Inc. (KR) | 2024-06-26 | — | — | EP | disclosed |
| CN-118063461-A | Red light/near infrared photochromic molecule, preparation method and application thereof | 华东理工大学 | 2024-05-24 | — | — | CN | disclosed |
| WO-2024091882-A1 | SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-05-02 | — | — | WO | disclosed |
| US-11917913-B2 | Substituted oxepines | MERCK PATENT GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-11917913-B2 | Substituted oxepines | MERCK PATENT GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-5977062-A | ACTIVE AGAINST ANTIBIOTIC RESISTANT BACTERIA | ELI LILLY AND COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
| US-5840684-A | Glycopeptide antibiotic derivatives | ELI LILLY AND COMPANY (US) | 1998-11-24 | — | — | US | disclosed |
| EP-0420397-B1 | Fulgimide derivatives | WAKO PURE CHEM IND LTD (JP) | 1995-11-29 | — | — | EP | disclosed |
| WO-1995020637-A2 | HYDROCARBON OIL-AQUEOUS FUEL AND ADDITIVE COMPOSITIONS | MEG S.N.C. DI SCOPELLITI SOFIA & C. (IT) | 1995-08-03 | — | — | WO | disclosed |
| US-5359085-A | Exhibits photochromic properties | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1994-10-25 | — | — | US | disclosed |
| EP-0420397-A1 | Fulgimide derivatives | WAKO PURE CHEMICAL INDUSTRIES LTD (JP) | 1991-04-03 | — | — | EP | disclosed |
| EP-0032432-B1 | PROSTANOID COMPOUNDS AND THEIR PREPARATION AND PHARMACEUTICAL FORMULATIONS | GLAXO GROUP LIMITED (GB) | 1985-07-24 | — | — | EP | disclosed |
| US-4438111-A | PROSTAGLANDINS, ANTICOAGULANTS, ANTIASTHMA | GLAXO GROUP LIMITED (GB) | 1984-03-20 | — | — | US | disclosed |
| EP-0032432-A1 | Prostanoid compounds and their preparation and pharmaceutical formulations | GLAXO GROUP LIMITED (GB) | 1981-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11917913-B2 | Substituted oxepines | OXGR1, OXTR, OCIAD2 | HSD17B1 4820/4885HSD17B2 4571/4885CYP2E1 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.